my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT07516353
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
15 Years - 24 Years
Healthy Volunteers
Not accepted

Interventions

  • my.naviGATE Digital Tool — BEHAVIORAL
    : A HIPAA-compliant digital health intervention in the form of a mobile application that provides personalized cancer survivorship education based on individual treatment regimens, virtual visits with trained peer navigators, and collection questionnaires/survey responses.

Study Details

This study aims to design and test a novel, personalized digital intervention-my.naviGATE-for adolescent and young adults (AYA) with cancer. my.naviGATE is a mobile app that provides personalized survivorship education, access to virtual peer navigation, and responsive participant-reported outcomes (PROs).

Key Dates

Start date
Aug 20, 2026
Status verified
Mar 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2030

Study Design

Enrollment
143 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • Experimental: my.naviGATE Group
    Participants will be randomized in a 1:1 ratio to this study group and will complete the following: * Baseline survey * 1 month survey * 6 month survey * Virtual interview (subset of participants)
  • No Intervention: Usual Care Group
    Participants will be randomized in a 1:1 ratio to this study group and will receive standard oncology care and will complete the following: * Baseline survey * 1 month survey * 6 month survey

Primary Outcome Measure

Change in Patient Activation Measure (PAM)-13 Score from Baseline to 6 Months Post-EOT [ Time Frame: Assessed at baseline, 1-month post EOT (+2 months) and 6-months post EOT (+2 months) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Dana Farber Cancer InstituteBostonMassachusetts02215
Katie Greenzang, MD
[email protected]
6176325992
Katie Greenzang, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
Leukemia (other)Brain cancer
By specialty
OncologyBlood cancerNeuro-oncology
By research site
Dana Farber Cancer Institute· Boston, MA

Related Studies